Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disea...(etic versions of genesencoding internal ...),Health

Date:8/19/2008

etic versions of genes encoding internal and surface proteins from different HIV subtypes. The combination is designed to provide protection against the most prevalent HIV strains circulating in Europe, Africa and The Americas. The prime-boost approach uses two vaccine components given at different times. The two vaccine components differ in how the genes are packaged. The DNA prime vaccine component contains only the specific gene sequences in a plasmid DNA ring, and cannot reconstitute into an infectious virus. The HIV DNA vaccine was developed by the SMI and the Karolinska Institute in Sweden. The viral vector boost vaccine component uses a Modified Vaccinia Ankara (MVA) virus (the virus that causes cowpox) to shuttle the same non-infectious gene sequences into the body. The boost vaccine component was developed by the NIH and Walter Reed Army Institute of Research, and does not use an adjuvant.

In the first Phase 1 trial, the DNA priming vaccines were delivered with the Biojector(R) 2000 needle-free injection system into either the muscle or the skin. In the next trial, the Vaxfectin(R)-formulated DNA vaccines would be delivered with the Biojector(R) 2000 needle-free injection system into the skin. The MVA boost vaccine is delivered by needle and syringe.

Recently reported preliminary results from Vical's Phase 1 trial of the company's H5N1 pandemic influenza DNA vaccines marked the first time the Vaxfectin(R) adjuvant was tested in humans. Some cohorts were vaccinated by needle and syringe into the muscle and some with the Biojector(R) 2000 needle- free injection system into the muscle. The proposed Karolinska/SMI study would mark the first human test of a Vaxfectin(R)-formulated vaccine delivered by needle-free injection into the skin. Intradermal delivery by needle-free injection and use of the Vaxfectin(R) adjuvant may increase the immune responses to the vaccine.

About Vaxfectin(R)

Vaxfectin(R) was designed by Vical to increase t
'/>"/>

SOURCE Vical Incorporated Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
2. New Implant Device Remotely Monitors Heart Failure Patients at Northwestern Memorials Bluhm Cardiovascular Institute
3. Seattles Swedish Cancer Institute First in U.S. to Treat Cancer Patient with Elekta VMAT
4. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
5. Banner Alzheimers Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimers Disease
6. Karmanos Cancer Institute Researchers Show Phase I Immunotherapy with Armed T Cells Improve Overall Survival of Metastatic Breast Cancer Patients
7. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
8. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
9. Transgenomic Establishes Collaboration With the National Cancer Institute to Investigate Mitochondrial Genome and Associated Nuclear Genes in Cancer Cell Lines
10. Karmanos Cancer Institute Research Supports Role of Inflammation to Determine Lung Cancer Risk, Particularly in African-American Women
11. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type